SG11202101652PA - Antibodies binding to citrullinated histone 2a and/or 4 - Google Patents
Antibodies binding to citrullinated histone 2a and/or 4Info
- Publication number
- SG11202101652PA SG11202101652PA SG11202101652PA SG11202101652PA SG11202101652PA SG 11202101652P A SG11202101652P A SG 11202101652PA SG 11202101652P A SG11202101652P A SG 11202101652PA SG 11202101652P A SG11202101652P A SG 11202101652PA SG 11202101652P A SG11202101652P A SG 11202101652PA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies binding
- citrullinated histone
- citrullinated
- histone
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1813597.0A GB201813597D0 (en) | 2018-08-21 | 2018-08-21 | Antibody |
GBGB1900983.6A GB201900983D0 (en) | 2019-01-24 | 2019-01-24 | Antibody |
PCT/EP2019/072302 WO2020038963A1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101652PA true SG11202101652PA (en) | 2021-03-30 |
Family
ID=67688785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101652PA SG11202101652PA (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20210395350A1 (en) |
EP (1) | EP3841120A1 (en) |
JP (1) | JP7434328B2 (en) |
KR (1) | KR20210056355A (en) |
CN (1) | CN112930356A (en) |
AU (1) | AU2019326740A1 (en) |
CA (1) | CA3110013A1 (en) |
IL (1) | IL280995A (en) |
MX (1) | MX2021001902A (en) |
SG (1) | SG11202101652PA (en) |
WO (1) | WO2020038963A1 (en) |
ZA (1) | ZA202101051B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
US10940204B2 (en) | 2015-07-31 | 2021-03-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
WO2021209465A1 (en) * | 2020-04-14 | 2021-10-21 | Universiteit Maastricht | Peptide for the treatment of net-associated diseases |
JP2023533504A (en) * | 2020-07-07 | 2023-08-03 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Combination therapy for biofilm treatment and prevention |
GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
CA2726511C (en) | 2008-06-04 | 2018-07-10 | Modiquest B.V. | Anti-inflammatory agents |
DK2334705T3 (en) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | BIOLOGICAL PRODUCTS |
EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
GB201410520D0 (en) * | 2014-06-12 | 2014-07-30 | Univ London Queen Mary | Antibody |
CN107108725B (en) | 2014-12-11 | 2021-03-23 | 莫蒂克斯特私人有限公司 | Methods of treating idiopathic pulmonary fibrosis |
EP3332256A1 (en) | 2015-08-06 | 2018-06-13 | NovImmune SA | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
-
2019
- 2019-08-20 US US17/269,509 patent/US20210395350A1/en not_active Abandoned
- 2019-08-20 KR KR1020217008362A patent/KR20210056355A/en unknown
- 2019-08-20 CA CA3110013A patent/CA3110013A1/en active Pending
- 2019-08-20 CN CN201980070130.3A patent/CN112930356A/en active Pending
- 2019-08-20 JP JP2021534820A patent/JP7434328B2/en active Active
- 2019-08-20 MX MX2021001902A patent/MX2021001902A/en unknown
- 2019-08-20 WO PCT/EP2019/072302 patent/WO2020038963A1/en unknown
- 2019-08-20 EP EP19756180.6A patent/EP3841120A1/en active Pending
- 2019-08-20 SG SG11202101652PA patent/SG11202101652PA/en unknown
- 2019-08-20 AU AU2019326740A patent/AU2019326740A1/en active Pending
-
2021
- 2021-02-16 ZA ZA2021/01051A patent/ZA202101051B/en unknown
- 2021-02-21 IL IL280995A patent/IL280995A/en unknown
- 2021-07-06 US US17/368,720 patent/US11345750B2/en active Active
-
2022
- 2022-05-27 US US17/827,488 patent/US20230183327A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210395350A1 (en) | 2021-12-23 |
EP3841120A1 (en) | 2021-06-30 |
US20230183327A1 (en) | 2023-06-15 |
JP7434328B2 (en) | 2024-02-20 |
MX2021001902A (en) | 2021-05-27 |
US20210403543A1 (en) | 2021-12-30 |
CA3110013A1 (en) | 2020-02-27 |
US11345750B2 (en) | 2022-05-31 |
CN112930356A (en) | 2021-06-08 |
AU2019326740A1 (en) | 2021-03-18 |
JP2021535211A (en) | 2021-12-16 |
ZA202101051B (en) | 2022-08-31 |
IL280995A (en) | 2021-04-29 |
KR20210056355A (en) | 2021-05-18 |
WO2020038963A1 (en) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280995A (en) | Antibodies binding to citrullinated histone 2a and/or 4 | |
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL278924A (en) | Antibodies specific for gucy2c and uses thereof | |
IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
SG11202101675UA (en) | Anti-bcma single domain antibodies and application thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
IL287816A (en) | Antibody to tigit and use thereof | |
ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
EP4036116A4 (en) | Anti-vhh domain antibodies and use thereof | |
SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
IL287479A (en) | Cd19 binding molecules and uses thereof | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL282707A (en) | Anti-tim-3 antibodies and their use | |
IL282708A (en) | Anti-tim-3 antibodies and their use | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
IL277969A (en) | Antibodies binding pd-1 and uses thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
EP3805265A4 (en) | Antibody binding to tie2 and use thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof |